GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: Meda (STO:MEDAA) has signed a long-term license agreement with the specialty division of Mylan Inc. (Nasdaq: MYL), Dey Pharma, L.P., for exclusive marketing and distribution rights of EpiPen® (epinephrine) Auto-Injector in Europe. EpiPen is used for emergency treatment of severe allergic reactions (anaphylaxis). Anaphylaxis can occur quickly (often within a couple of minutes) and may be life-threatening.
